The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Regulation of Bim in Health and Disease
Open accessAbstract
// Ronit Vogt Sionov 1 , Spiros A. Vlahopoulos 2 and Zvi Granot 1 1 Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel Canada, Hebrew University, Hadassah Medical School, Jerusalem, Israel 2 First Department of Pediatrics, University of Athens, Horemeio Research Laboratory, Thivon and Levadias, Goudi, Athens, Greece Correspondence to: Ronit Vogt Sionov, email: // Keywords : Bim, apoptosis, cancer, autoimmunity, neurodegenerative diseases Received : July 28, 2015 Accepted : August 08, 2015 Published : September 05, 2015 Abstract The BH3-only Bim protein is a major determinant for initiating the intrinsic apoptotic pathway under both physiological and pathophysiological conditions. Tight regulation of its expression and activity at the transcriptional, translational and post-translational levels together with the induction of alternatively spliced isoforms with different pro-apoptotic potential, ensure timely activation of Bim. Under physiological conditions, Bim is essential for shaping immune responses where its absence promotes autoimmunity, while too early Bim induction eliminates cytotoxic T cells prematurely, resulting in chronic inflammation and tumor progression. Enhanced Bim induction in neurons causes neurodegenerative disorders including Alzheimer’s, Parkinson’s and Huntington’s diseases. Moreover, type I diabetes is promoted by genetically predisposed elevation of Bim in β-cells. On the contrary, cancer cells have developed mechanisms that suppress Bim expression necessary for tumor progression and metastasis. This review focuses on the intricate network regulating Bim activity and its involvement in physiological and pathophysiological processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
FoxOs Are Critical Mediators of Hematopoietic Stem Cell Resistance to Physiologic Oxidative Stress
Tothova, Z., Kollipara, R., Huntly, B. J., Lee, B. H., Castrillon, D. H., Cullen, D. E., McDowell, E. P., Lazo-Kallanian, S., Williams, I. R., Sears, C., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.003 · Cited by 1,562 · cited 1×
“As FoxO3 KO mice show altered hematopoietic homeostasis [147-149], it is likely that FoxO3a may affect Bim transcription through interaction with other transcription factors, or that there is a compensation for FoxO3.”
BackgroundKuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis
Lei, K., & Davis, R. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0438011100 · Cited by 1,068
Regulation and function of mTOR signalling in T cell fate decisions
Chi, H. (2012) · Nature Reviews Immunology · doi:10.1038/nri3198 · Cited by 1,035
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876 · cited 1×
“ABT-263 (Navitoclax) is a clinical derivative of ABT-737 that are currently undergoing phase I and II clinical evaluation in various tumor types including leukemia [580-582].”
BackgroundIκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
Hu, M. C.-T., Lee, D.-F., Xia, W., Golfman, L. S., Ou-Yang, F., Yang, J.-Y., Zou, Y., Bao, S., Hanada, N., Saso, H., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00302-2 · Cited by 868
VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis
Cheng, E. H.-Y., Sheiko, T. V., Fisher, J. K., Craigen, W. J., & Korsmeyer, S. J. (2003) · Science · doi:10.1126/science.1083995 · Cited by 852
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 1×
“NVPBGT226 has also been shown to exert cytotoxic effects against other cancer cell types such as ALK-positive anaplastic large cell lymphoma [615] and hepatocellular carcinoma [616] and has entered Phase I/II clinical trials for breast cancer [617].”
BackgroundBH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes
Bouillet, P., Purton, J. F., Godfrey, D. I., Zhang, L.-C., Coultas, L., Puthalakath, H., Pellegrini, M., Cory, S., Adams, J. M., & Strasser, A. (2002) · Nature · doi:10.1038/415922a · Cited by 782
BAX activation is initiated at a novel interaction site
Gavathiotis, E., Suzuki, M., Davis, M. L., Pitter, K., Bird, G. H., Katz, S. G., Tu, H.-C., Kim, H., Cheng, E. H.-Y., Tjandra, N., et al. (2008) · Nature · doi:10.1038/nature07396 · Cited by 700 · cited 2×
“In addition, Bim can directly interact with Bax and Bak, leading to mitochondrial outer membrane permeabilization [7-11].”
BackgroundPuthalakath, H., Villunger, A., O'Reilly, L. A., Beaumont, J. G., Coultas, L., Cheney, R. E., Huang, D. C. S., & Strasser, A. (2001) · Science · doi:10.1126/science.1062257 · Cited by 656 · cited 1×
“Bim is also released from microtubule following paclitaxel (Taxol) treatment that interferes with the normal breakdown of microtubules during cell division [91].”
BackgroundDeubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Stepwise Activation of BAX and BAK by tBID, BIM, and PUMA Initiates Mitochondrial Apoptosis
Kim, H., Tu, H.-C., Ren, D., Takeuchi, O., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J.-D., & Cheng, E. H.-Y. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.030 · Cited by 600 · cited 3×
“Activator BH3-only proteins remain associated with the N-terminally exposed Bax through the BH1 domain to drive homo-oligomerization [69].”
BackgroundNg, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477
The human SWI/SNF subunit Brm is a regulator of alternative splicing
Batsché, E., Yaniv, M., & Muchardt, C. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1030 · Cited by 471
Leverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
BH3-Triggered Structural Reorganization Drives the Activation of Proapoptotic BAX
Gavathiotis, E., Reyna, D. E., Davis, M. L., Bird, G. H., & Walensky, L. D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.019 · Cited by 310
Enders, A., Bouillet, P., Puthalakath, H., Xu, Y., Tarlinton, D. M., & Strasser, A. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030411 · Cited by 295
mTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · cited 1×
“Mcl-1 is a short-lived protein, positively regulated by the mTOR signaling pathway, while negatively by the E3 ligases Mcl-1 ubiquitin ligase E3 (Mule), F-Box and WD repeat domain containing 7 (Fbw7), Tripartite motif containing 17 (Trim17) and β-transducin repeat containing E3 ubiquitin protein ligase 1 (β-TrCP1), th…”
BackgroundBIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors
Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0106 · Cited by 283 · cited 5×
“Bim RNA levels may be assessed in diagnostic cancer specimens to predict which patients will benefit from single-agent kinase inhibitor [618].”
BackgroundInfluentialCosta, C., Molina, M. A., Drozdowskyj, A., Giménez-Capitán, A., Bertran-Alamillo, J., Karachaliou, N., Gervais, R., Massuti, B., Wei, J., Moran, T., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2233 · Cited by 229 · cited 2×
“Those with higher Bim expression showed longer progression-free survival when treated with the EGFR tyrosine kinase inhibitor erlotinib and longer overall survival [546-548].”
BackgroundMultisite Phosphorylation Regulates Bim Stability and Apoptotic Activity
Hübner, A., Barrett, T., Flavell, R. A., & Davis, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.025 · Cited by 228
Jang, S.-W., Yang, S.-J., Srinivasan, S., & Ye, K. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704542200 · Cited by 133
Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127 · cited 2×
“Small-cell lung cancer (SCLC) with high Bim expression is among the most sensitive cells to ABT-263 treatment [584].”
BackgroundFaber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124
Corazza, N., Jakob, S., Schaer, C., Frese, S., Keogh, A., Stroka, D., Kassahn, D., Torgler, R., Mueller, C., Schneider, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27726 · Cited by 123
Characterization of the c-Jun N-Terminal Kinase-BimELSignaling Pathway in Neuronal Apoptosis
Becker, E. B. E., Howell, J., Kodama, Y., Barker, P. A., & Bonni, A. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2953-04.2004 · Cited by 116 · cited 1×
“Most of the studies showed JNKmediated phosphorylation of BimEL in neurons [156, 324], while ERK-mediated phosphorylation is mainly detected in non-neuronal cells [297, 300, 325].”
BackgroundCTSH regulates β-cell function and disease progression in newly diagnosed type 1 diabetes patients
Fløyel, T., Brorsson, C., Nielsen, L. B., Miani, M., Bang-Berthelsen, C. H., Friedrichsen, M., Overgaard, A. J., Berchtold, L. A., Wiberg, A., Poulsen, P., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402571111 · Cited by 104
Cleary, J. M., Lima, C. M. S. R., Hurwitz, H. I., Montero, A. J., Franklin, C., Yang, J., Graham, A., Busman, T., Mabry, M., Holen, K., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0110-9 · Cited by 80
Transforming Growth Factor-β1 (TGF-β1) Induces Human Osteoclast Apoptosis by Up-regulating Bim
Houde, N., Chamoux, E., Bisson, M., & Roux, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.019372 · Cited by 80
Anoikis evasion in inflammatory breast cancer cells is mediated by Bim-EL sequestration
Buchheit, C. L., Angarola, B. L., Steiner, A., Weigel, K. J., & Schafer, Z. T. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.209 · Cited by 63
Wang, E., Kawaoka, S., Roe, J.-S., Shi, J., Hohmann, A. F., Xu, Y., Bhagwat, A. S., Suzuki, Y., Kinney, J. B., & Vakoc, C. R. (2015) · eLife · doi:10.7554/elife.06377 · Cited by 54 · cited 1×
“1, leading to suppression of Bim expression and protection of B lymphoblastic leukemia from apoptosis [209].”
BackgroundBIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis
Weber, K., Harper, N., Schwabe, J., & Cohen, G. M. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.09.010 · Cited by 41
Sanphui, P., Pramanik, S. K., Chatterjee, N., Moorthi, P., Banerji, B., & Biswas, S. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078842 · Cited by 38
Epigenetic silencing of Bim transcription by Spi-1/PU.1 promotes apoptosis resistance in leukaemia
Ridinger-Saison, M., Evanno, E., Gallais, I., Rimmelé, P., Selimoglu-Buet, D., Sapharikas, E., Moreau-Gachelin, F., & Guillouf, C. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2013.88 · Cited by 34
Ying, H.-Q., Chen, J., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Sun, H.-L., Liu, X., & Wang, S.-K. (2015) · Scientific Reports · doi:10.1038/srep11348 · Cited by 29 · cited 2×
“Bim deletion polymorphism was significantly associated with the clinical efficacy of tyrosine kinase inhibitors in terms of response rate and disease control rate in EGFR-mutated NSCLC patients, but not in CML or hepatocellular carcinoma (HCC) [639].”
BackgroundGagné, V., Rousseau, J., Labuda, M., Sharif-Askari, B., Brukner, I., Laverdière, C., Ceppi, F., Sallan, S. E., Silverman, L. B., Neuberg, D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1215 · Cited by 28
Cited by
Pathogenic mechanisms following ischemic stroke
Khoshnam, S. E., Winlow, W., Farzaneh, M., Farbood, Y., & Moghaddam, H. F. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2938-1 · Cited by 621
BCL-2 protein family: attractive targets for cancer therapy
Kaloni, D., Diepstraten, S. T., Strasser, A., & Kelly, G. L. (2023) · Apoptosis · doi:10.1007/s10495-022-01780-7 · Cited by 500
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Genetics of primary sclerosing cholangitis and pathophysiological implications
Jiang, X., & Karlsen, T. H. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.154 · Cited by 155
Metadata
- Authors
- Sionov, R. V., Vlahopoulos, S. A., & Granot, Z.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-09-05
- Volume
- 6
- Issue
- 27
- Pages
- 23058-23134
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1884243320
- Cited by
- 216
- References
- 46
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.